[HTML] frontiersin.org

[HTML][HTML] SARS-CoV-2: recent variants and clinical efficacy of antibody-based therapy

DD Singh, A Sharma, HJ Lee… - Frontiers in cellular and …, 2022 - frontiersin.org
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …
被引用次数：21 相关文章

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

DD Singh, A Sharma, HJ Lee… - COVID-19: New Variants …, 2022 - books.google.com
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2
variants and B. 1.1. 529. Possible options for VOC are urgently required as they carry …

SARS-CoV-2: recent variants and clinical efficacy of antibody-based therapy.

DD Singh, A Sharma, HJ Lee, DK Yadav - 2022 - cabidigitallibrary.org
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

DD Singh, A Sharma, HJ Lee, DK Yadav - 2022 - agris.fao.org
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.

DD Singh, A Sharma, HJ Lee… - Frontiers in Cellular & …, 2022 - search.ebscohost.com
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

DD Singh, A Sharma, HJ Lee… - Frontiers in cellular …, 2022 - pubmed.ncbi.nlm.nih.gov
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.

DD Singh, A Sharma, HJ Lee… - Frontiers in Cellular and …, 2022 - europepmc.org
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

DD Singh, A Sharma, HJ Lee, DK Yadav - 2022 - scholarworks.bwise.kr
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …
[PDF] scienceopen.com

[PDF][PDF] SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

DD Singh, A Sharma, HJ Lee… - Front. Cell. Infect …, 2022 - scienceopen.com
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …
[PDF] academia.edu

[PDF][PDF] SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

DD Singh, A Sharma, HJ Lee… - Front. Cell. Infect. Microbiol …, 2022 - academia.edu
Multiple variants of SARS-CoV-2 have emerged and are now prevalent at the global level.
Currently designated variants of concern (VOCs) are B. 1.1. 7, B1. 351, P. 1, B. 1.617. 2 …